TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Michel Janicot, Ph.D
Chief Development Officer at InteRNA Technologies

Profile

Dr. M. Janicot holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from the University of Paris VII (France) and was Postdoctoral Fellow in the Dept. of Biological Chemistry (M. Daniel Lane) at The Johns Hopkins University (Baltimore, MD. USA). He has over 25-years hands-on experience in Oncology preclinical and early clinical pharmaceutical drug development in increasing leadership and managerial roles at Rhone-Poulenc Rorer (Sanofi) and subsequently, at Janssen (Johnson & Johnson). Since 2012, Michel is the Founder and Managing Director of JMi ONConsulting, a Brussels-based consulting firm specialized in providing services and guidance for (small molecules and biologicals) research and development programs in a wide range of clinical indications, including: Oncology, Inflammation, Immunology, Vaccines, COPD, MS, Diabetes, Fibrosis and Ophthalmology. In this context, Michel is (has been) involved in several oligonucleotide-based therapeutic approaches: antisense oligonucleotides, miRNAs, aptamers, and mRNAs. Michel is also co-founder and Board member of aPODD, a non-profit foundation focusing on Pediatric Oncology Drug Development.

Michel Janicot, Ph.D's Network

Agenda Sessions

  • MicroRNAs - An Emerging Attractive Drug Discovery Platform for Therapeutic Intervention in Oncology

    , 18:00

Speakers at this event